Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation

Daniele Pastori; Pasquale Pignatelli; Francesco Cribari; Roberto Carnevale; Mirella Saliola; Francesco Violi; Professor Gregory Lip

doi:10.1016/j.ahj.2018.03.004

Shared by

Professor Gregory Lip

University of Liverpool

Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation

Article 2018 en

Authors

DP
Daniele Pastori
PP
Pasquale Pignatelli
FC
Francesco Cribari

Related publications

Article2023

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists

Hanis Hanum Zulkifly, Daniele Pastori, Deirdre A. Lane, Professor Gregory Lip

Article2017

Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists

José María Lobos-Bejarano, Ángel Castellanos Rodríguez, Vivencio Barrios, Carlos Escobar, José Polo García, José Carlos del Castillo-Rodríguez, Diego Vargas-Ortega, Adriana López‐Pineda, Luís Prieto, Professor Gregory Lip

Article2018

Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

Daniele Pastori, Alessio Farcomeni, Mirella Saliola, Francesco Del Sole, Pasquale Pignatelli, Francesco Violi, Professor Gregory Lip, Marco Casciaro, Domenico Ferro, Danilo Menichelli, Roberto Carnevale, Fabiana Albanese, Tiziana Di Stefano, Patrizia Iannucci, Elio Sabbatini, Claudia Iannilli

Article2022

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

Vanessa Roldán, Lorena Martínez-Montesinos, Raquel López‐Gálvez, Lucía García-Tomás, Professor Gregory Lip, José Miguel Rivera‐Caravaca, Francisco Marı́n

Article2019

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation

Hee Tae Yu, Pil‐Sung Yang, Jinseub Hwang, Soorack Ryu, Eunsun Jang, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Professor Gregory Lip, Boyoung Joung

Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation

Discussion(0)

Related publications

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists

Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists

Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation